Last updated on July 2017

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer


Brief description of study

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)

Clinical Study Identifier: NCT02657889

Contact Investigators or Research Sites near you

Start Over

Clinical Trial Management Group

Birmingham, AL United States
  Connect »

Clinical Trial Management Group

Scottsdale, AZ United States
  Connect »

Clinical Trial Management Group

Los Angeles, CA United States
  Connect »

Clinical Trial Management Group

San Francisco, CA United States
  Connect »

Julie Castle

Washington, D.C., United States
  Connect »

Clinical Trial Management Group

Jacksonville, FL United States
  Connect »

Kathleen Manning

Miami, FL United States
  Connect »

Clinical Trial Management Group

Burlington, MA United States
  Connect »

Meghan Wyse

Detroit, MI United States
  Connect »

Clinical Trial Management Group

Morristown, NJ United States
  Connect »

Lori Megherian

Lake Success, NY United States
  Connect »

Nicole Whitman

Chapel Hill, NC United States
  Connect »

Audrie Walls

Charlotte, NC United States
  Connect »

Cancer Information Services

Cleveland, OH United States
  Connect »

Ingrid Block

Oklahoma City, OK United States
  Connect »

Nicole Holloway

Memphis, TN United States
  Connect »

Lisa Creighton

San Antonio, TX United States
  Connect »

Natalie Salsini

Charlottesville, VA United States
  Connect »